



# EFSA remit & role: with focus on scientific substantiation of Health Claims made on foods

**EFSA meeting with IPA Europe**

Parma, 18 January 2019

# OUTLINE

- EFSA legal framework & remit
- EFSA principles for scientific substantiation of claims
- Experience from health claim substantiation
- EFSA vs. non-EU jurisdictions
- EFSA guidance documents

# RISK ASSESSMENT & RISK MANAGEMENT IN THE EU



*Scientific  
assessment*



*Policy, legislation,  
authorisation...*

**European Commission**  
**European Parliament**  
**European Council**  
**EU Member States**

# REMIT

## *EFSA Founding Regulation (EC) 178/2002*

### *EFSA does not*

- Develop or propose policies, legislation, norms and standards
- Enforce legislation
- Classification of products as food/food category
- Authorise products & nutrition/health claims made on foods
- Take charge of food safety/quality controls
- Setting labelling requirements
- Make recommendations to consumers
- Monitor or assess consumers' behaviour, societal/economical aspects



***These are for Risk Managers***

# HEALTH CLAIMS MADE ON FOODS: LEGAL FRAMEWORK

## *Regulation (EC) No 1924/2006*

Health claims should only be authorised in the EU after **a scientific assessment of the highest possible standard**

Claims substantiated  
by

 **generally accepted scientific evidence**

 **totality of the available scientific data**

 **weighing the evidence**

EFSA NDA Panel adopts scientific opinions



**AUTHORISATION: by Commission/Member States, European Parliament scrutiny**

# HEALTH CLAIMS ON FOODS: REGULATORY REQUIREMENTS

## *Regulation (EC) No 1924/2006 and (EU) No 1169/2011*

- ❑ Food category, a food or a food constituent (e.g. a nutrient or other substance, or a fixed combination of nutrients/other substances)
- ❑ Function claims **cannot** refer to a disease
- ❑ Disease risk reduction claims **cannot** refer to reduction of the risk of a disease, but to reduction of a risk factor for disease
- ❑ Subjects with a disease **cannot** be the target population for claims made on food
  - ❑ Target population for claims = **general (healthy) population or subgroups thereof**
- ❑ **Efficacy assessment**. No safety assessment

# PRINCIPLES FOR SCIENTIFIC SUBSTANTIATION

## General scientific guidance for stakeholders on health claim applications

**A food/constituent**



**A claimed effect**

1. Is the food/constituent **characterised**?
2. Is the claimed effect based on **the essentiality of a nutrient**? OR  
Is the claimed effect **defined** and is it a **beneficial physiological effect**, and can **be measured *in vivo* in humans**?
3. Is a **cause and effect relationship** established between the consumption of the food/constituent and the claimed effect?
  - ✓ for the **target population** and under the **proposed conditions of use (CoU)**

**Scientific substantiation (positive outcome) requires a favourable outcome to ALL three questions**

# PRINCIPLES FOR SCIENTIFIC SUBSTANTIATION (cont.)

## General scientific guidance for stakeholders on health claim applications

### Characterisation of the food/constituent

#### i. Composition/characteristics

**plant sterols/stanols** LDL-cholesterol  
**resistant starch** post-prandial blood glucose  
**sugar-free gum** tooth mineralisation

#### ii. Manufacturing process

**water-soluble tomato concentrate**  
standardised by the total of 37 constituents  
inhibiting platelet aggregation *in vitro*

#### iii. Known mechanism of action

**non-digestible carbohydrates**  
post-prandial blood glucose


**For a food category:** Whether the information provided sufficiently addresses the variability between individual foods regarding those characteristics which may influence the specific claimed effect?



# PRINCIPLES FOR SCIENTIFIC SUBSTANTIATION (cont.)

## General scientific guidance for stakeholders on health claim applications

### Characterisation of microorganisms








- ❑ **Species identification + strain characterisation/typing** needed, since effects are strain specific unless the contrary is demonstrated
- ❑ New **molecular tools** (multilocus sequence typing, optical mapping, whole-genome sequencing, etc.). Open list to others.
- ❑ **Several methods** often needed in combination

# PRINCIPLES FOR SCIENTIFIC SUBSTANTIATION (cont.)

## General scientific guidance for stakeholders on health claim applications

### Characterisation of the claimed effect

-  the human studies submitted
-  Identify the health/disease **outcome(s)** in relation to the food/constituent and for which the available evidence may be strong
-  Do outcome(s) describe **a beneficial physiological effect?**
-  Are outcome variable(s) direct measures of the claimed effect?
-  Are the **assessment methods** appropriate?

# PRINCIPLES FOR SCIENTIFIC SUBSTANTIATION (cont.)


## General scientific guidance for stakeholders on health claim applications

### □ Pertinent human efficacy studies (central for substantiation) – hierarchy of evidence

- ✓ carried out with **the food/constituent for the claim**?
- ✓ **appropriate outcome measure(s)** for the claimed effect?
- ✓ **study group** is representative of the target population?
- ✓ **the design and quality of the study** in relation to the risk of bias?
- ✓ **conditions for human studies** vs. conditions of use for the claim?

□ **Supportive studies:** Efficacy studies in animals, non-efficacy studies in humans, animals/*in vitro* (e.g. mechanisms that explain the effect of the food)

□ **Weighing the evidence:** combining human efficacy studies +supportive studies +biological plausibility of the effect to conclude on substantiation



# EXPERIENCE FROM HEALTH CLAIM SUBSTANTIATION

## Insufficient characterisation of the food/constituent

**a major reason for unfavourable opinions related to microorganisms in 2009/2010**

- Non-characterised microorganisms (87%)
- Characterised microorganisms (13%)



## EXPERIENCE FROM HEALTH CLAIM SUBSTANTIATION (cont.)

### Insufficient characterisation of the claimed effect other major reason for unfavourable opinions

- **Non defined claims:**

'gut health', 'digestive health',  
'healthy microbiota', 'natural  
defences' etc.

**specific and  
measurable**



- **Non beneficial claims:**

'reduction of gastric acid levels',  
'reduction of inflammation'

**is a beneficial  
physiological effect  
for the target  
population**




## EXPERIENCE FROM HEALTH CLAIM SUBSTANTIATION (cont.)

### Insufficient characterisation of the claimed effect

Not all outcomes, which can be measured *in vivo* in humans by generally accepted methods, reflect a direct benefit on human physiology



E.g. Changes in the composition of the gut microbiota / immune markers *per se* / SCFA



Adapted from NaturalMed Apothecary, Inc. 2006

# EXPERIENCE FROM HEALTH CLAIM SUBSTANTIATION (cont.)

## Lack of pertinent human studies

Altern Ther Health Med. 2011 Jan-Feb;17(1):72-9.

### **Clinical utility of probiotics in inflammatory bowel disease.**

Cain AM, Karpa KD.

York Hospital, Pennsylvania, USA.

Curr Opin Pediatr. 2010 Oct;22(5):626-34.

### **Probiotics and prebiotics in allergic disease.**

Tang ML, Lathigal T.

Paediatr Allergy Immunology, Royal Children's Hospital, Parkville, VIC, Australia. mimi.tang@rch.org.au

Paediatr Allergy Immunology 2010 Aug 25;10:253.

### **Probiotics in the treatment of acute rotavirus diarrhoea. A randomized, double-blind, controlled trial using two different probiotic preparations in Bolivian children.**

Grandy G, Medina M, Soria R, Terán CG, Araya M.

Paediatric Centre Albina Patiño, Department of Gastroenterology and Nutrition, Cochabamba, Bolivia. ggrandy@inta.cl

**Studies designed for the treatment of diseases**

# EXPERIENCE FROM HEALTH CLAIM SUBSTANTIATION (cont.)

## Peer-reviewed publications

**may not provide the evidence needed for scientific substantiation of health claims**

- ❑ **Aim of the publication** (human intervention/observational studies, meta-analysis of RCTs) **may not fit the purpose and conditions of the claim** (e.g. insufficient characterisation of the food/constituent, study group not representative of the target population, inappropriate outcome measures of the claimed effect)
- ❑ **Statistical analyses may be inappropriate in relation to the outcome measure of interest for the claim** (e.g. PP and/or ITT analyses based on a different outcome)
- ❑ **Relevance of findings may depend on the context** (e.g. hypothesis-generating, exploratory studies vs. confirmatory studies)



**The use and value of peer-reviewed publications depend on their purpose**



# EXPERIENCE FROM HEALTH CLAIM SUBSTANTIATION (cont.)

## Examples of authorised/non-authorised health claims (Art. 13.1)

Food/constituent	Health relationship	Reasons/outcomes
<b>Dietary fibre</b>	<ul style="list-style-type: none"> <li>• Maintain a healthy immune system;</li> <li>• Maintain normal blood lipid levels/a healthy cardiovascular system</li> <li>• Maintain healthy cholesterol levels</li> <li>• Maintain normal blood sugar levels</li> <li>• Low glycaemic response</li> <li>• Reduce fat absorption</li> <li>• Maintain your body weight</li> <li>• Maintain normal bowel/colonic function</li> </ul>	<p><b>Unfavourable evaluation:</b> <b>Not sufficiently characterised</b></p> <p><b>Non-authorised</b></p>
Arabinoxylan from wheat endosperm	Reduction of post-prandial glycaemic responses	<b>Favourable evaluation</b> <b>Authorised</b>
Rye fibre	Changes in bowel function	<b>Favourable evaluation</b> <b>Authorised</b>
Wheat bran fibre	↑ intestinal transit	<b>Favourable evaluation</b> <b>Authorised</b>

# EFSA vs NON-EU JURISDICTIONS



**Health claim assessments in different jurisdictions are often driven by different legislative frameworks governing the authorisation of health claims made on food!**

# ALTERNATIVES to HEALTH CLAIMS?

- “Probiotics” as generic descriptor**
- Nutrition claim “contains probiotics”**
- “Probiotics” as recognised food category (comparable to “dietary fibre”)**
- “Probiotics” in “positive list” (as Canada)**




**For consideration by EU Risk Managers  
(i.e. Member States and the European  
Commission)**

# EFSA GUIDANCE DOCUMENTS



- ❑ General scientific guidance for stakeholders on health claim applications
- ❑ Preparation and presentation of health claim application
- ❑ 6 guidance on specific health claims areas



- ❑ **Scientific Committee Guidance on the assessment of the biological relevance of data in scientific assessments**
  - generic issues/criteria to consider biological relevance, particularly when deciding on whether an observed effect is of biological relevance



## Subscribe to

[www.efsa.europa.eu/en/news/newsletters](http://www.efsa.europa.eu/en/news/newsletters)  
[www.efsa.europa.eu/en/rss](http://www.efsa.europa.eu/en/rss)



## Engage with careers

[www.efsa.europa.eu/en/engage/careers](http://www.efsa.europa.eu/en/engage/careers)



## Follow us on Twitter

[@efsa\\_eu](https://twitter.com/efsa_eu)  
[@plants\\_efsa](https://twitter.com/plants_efsa)  
[@methods\\_efsa](https://twitter.com/methods_efsa)